MODEL VERDICT
BridgeBio Oncology Therapeutics Inc. (BBOT)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Feb 28, 2026 | NEUTRAL | 0.14 | $10.03 | CURRENT | -19.6% |
| Feb 21, 2026 | NEUTRAL | 0.38 | $9.98 | Below threshold | -11.1% |
| Feb 14, 2026 | NEUTRAL | 0.12 | $11.25 | Below threshold | -16.5% |
| Feb 11, 2026 | NEUTRAL | 0.13 | $10.84 | Below threshold | -22.5% |
| Jan 11, 2026 | MODERATE | 0.65 | $13.19 | Monitoring | -36.3% |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| Industry Median P/E 48 industry peers | $9.68 | -3.5% | 15% | A | Peer Data |
| Earnings Yield 47 industry peers | $12.21 | +21.7% | 2% | B | Data |
| Weighted Output Blended model output | $9.83 | -2.0% | 100% | 44 | FAIRLY VALUED |
| EPS Growth ↓ | P/E Multiple → | 18× | 20× | 22× (Current) | 24× | 26× |
|---|---|---|---|---|---|
| Bear Case (4%) | $9 | $10 | $11 | $11 | $12 |
| Conservative (7%) | $9 | $10 | $11 | $12 | $13 |
| Base Case (10.0%) | $9 | $10 | $11 | $12 | $13 |
| Bull Case (14%) | $9 | $10 | $11 | $13 | $14 |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
Based on our peer multiples analysis with 4 valuation metrics, the model estimates BBOT's fair value at $9.83 vs the current price of $10.03, implying -2.0% downside potential. Model verdict: Fairly Valued. Confidence: 44/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $9.83 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $1.86 (P10) to $20.24 (P90), with a median of $10.32.
BBOT's current P/E of 21.8x compares to the industry median of 21.0x (48 peers in the group). This represents a +3.6% premium to the industry. The historical average P/E is N/Ax over 0 years. Signal: Fair Value.
2 analysts cover BBOT with a consensus rating of Buy. The consensus price target is $23.33 (range: $18.00 — $27.00), implying +132.6% upside from the current price. Grade breakdown: Strong Buy (0), Buy (2), Hold (0), Sell (0), Strong Sell (0).
The model confidence score is 44/100, based on: data completeness (6), peer quality (25), historical depth (5), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for BBOT.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.